Clinical Trials Logo

TAR-DNA-binding Protein-43 clinical trials

View clinical trials related to TAR-DNA-binding Protein-43.

Filter by:
  • None
  • Page 1

NCT ID: NCT02166944 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Tamoxifen Treatment in Patients With Motor Neuron Disease

Start date: April 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to survey the effect of Tamoxifen in motor neuron disease (MND) patients, amyotrophic lateral sclerosis (ALS) with regular riluzole usage. TDP-43 is related to ALS. Increased the ubiquitinated or phosphorylated TDP-43 can cause animal model of ALS, and TDP43 can be degraded either by proteasome or autophagy pathway system. Autophagy pathway can be activated by mTOR inhibition, resulting in ameliorating TDP-43 accumulation and rescue in motor function in animal model. Tamoxifen had shown ability of enhance both proteasome and autophagy pathway, therefore the investigators assume that Tamoxifen probably can ameliorate TDP-43 accumulation and inclusion body formation in ALS.